Measurement of Fibrinogen in Patients With Systemic Inflammatory Response Syndrome (SIRS), Sepsis or Chronicle Liver Disease on Intensive Care Units (ICU)

Measurement of Fibrinogen in Patients With Systemic Inflammatory Response Syndrome, Sepsis, Chronicle Liver Disease or After Lysis on Intensive Care Units

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01169168

Enrollment

250

Registered

2010-07-26

Start date

2010-04-30

Completion date

Unknown

Last updated

2010-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Disease, Sepsis, SIRS

Keywords

fibrinogen, SIRS, sepsis, liver disease, chronic liver disease, septic shock

Brief summary

In this study patients with 1. chronicle liver diseases * primary biliary cirrhosis * primary sclerosing cholangitis * alcoholic liver cirrhosis * hepatitis b or C * Wilson's disease * cryptogenic cirrhosis 2. Septic Inflammatory Response Syndrome (SIRS) * sepsis * septic shock 3. patients after lysis should be included Blood samples will be gathered from the patients to measure fibrinogen with 5 different methods. The methods are: * Clauss fibrinogen * PT-Derived fibrinogen * immunoturbidimetric method * heat-precipitated fibrinogen * Schulz fibrinogen The result of these tests will be correlated with laboratory values which are gathered in routine and the clinical outcomes.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* SIRS * sepsis * septic shock * chronicle liver disease (MELD-Score \>10) * patient after lysis * patient agrees

Exclusion criteria

* no agreement

Design outcomes

Primary

Measure	Time frame	Description
Fibrinogen levels from 5 test methods	—	* Clauss fibrinogen * PT-Derived fibrinogen * immunoturbidimetric method * heat-precipitated fibrinogen * Schulz fibrinogen

Secondary

Measure	Time frame
Number of bleedings	—
Number of administered fresh frozen plasma	—
Number of administered erythrocyte concentrates	—
Number of administered thrombocyte concentrates	—
mortality	—

Countries

Germany

Outcome results